News | November 06, 2025
Zydus wellness reports 31% growth in net sales in Q2 FY26
During the quarter, Zydus Wellness completed the acquisition of Comfort Click Limited and its subsidiaries
During the quarter, Zydus Wellness completed the acquisition of Comfort Click Limited and its subsidiaries
Cupid has been allocated approximately 23.4 million units of female condoms per year
Bayer remains a key partner in Ginkgo Bioworks’ growing agricultural biologicals platform
Enzomenib, an oral, small-molecule inhibitor designed to disrupt the menin-MLL protein interaction involved in leukemogenesis
Kygevvi combines two pyrimidine nucleosides, doxecitine and doxribtimine, which act by integrating deoxycytidine and deoxythymidine into skeletal muscle mitochondrial DNA
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
This integrated center combines development, testing, evaluation, and industry-academia-research collaboration
Speakers are: Dr. Alok Khullar, Senior Technology Leader, Pidilite Industries; Dr. Kamlesh Pai Fondekar, Head - R&D, Godrej Agrovet; Dr. Hiten Mehta, Head - R&D (Chlor-Alkali), Aditya Birla Chemicals; Dr. Anil Kumar Soni, Head - Application Development, R&D, Clariant Chemicals India; Dr. Rupak Paul, Deputy General Manager – Formulation, Rallis India; Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals; and Pravin Prashant, Executive Editor, Indian Pharma Post
The company has introduced an innovative Dual Release Proton Pump Inhibitor (PPI) tablet, a next-generation therapy for patients suffering from moderate to severe or treatment resistant gastroesophageal reflux disease
Subscribe To Our Newsletter & Stay Updated
